Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study

Luca Bello, Heather Gordish-Dressman, Lauren P. Morgenroth, Erik K Henricson, Tina Duong, Eric P. Hoffman, Avital Cnaan, Craig M McDonald

Research output: Contribution to journalArticlepeer-review

86 Scopus citations


Objective: We aimed to perform an observational study of age at loss of independent ambulation (LoA) and side-effect profiles associated with different glucocorticoid corticosteroid (GC) regimens in Duchenne muscular dystrophy (DMD). Methods: We studied 340 participants in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS). LoA was defined as continuous wheelchair use. Effects of prednisone or prednisolone (PRED)/deflazacort (DFZ), administration frequency, and dose were analyzed by time-varying Cox regression. Side-effect frequencies were compared using χ 2 test. Results: Participants treated ≥1 year while ambulatory (n 252/340) showed a 3-year median delay in LoA (p <0.001). Fourteen different regimens were observed. Nondaily treatment was common for PRED (37%) and rare for DFZ (3%). DFZ was associated with later LoA than PRED (hazard ratio 0.294 ± 0.053 vs 0.490 ± 0.08, p 0.003; 2-year difference in median LoA with daily administration, p <0.001). Average dose was lower for daily PRED (0.56 mg/kg/d, 75% of recommended) than daily DFZ (0.75 mg/kg/d, 83% of recommended, p <0.001). DFZ showed higher frequencies of growth delay (p <0.001), cushingoid appearance (p 0.002), and cataracts (p <0.001), but not weight gain. Conclusions: Use of DFZ was associated with later LoA and increased frequency of side effects. Differences in standards of care and dosing complicate interpretation of this finding, but stratification by PRED/DFZ might be considered in clinical trials. This study emphasizes the necessity of a randomized, blinded trial of GC regimens in DMD. Classification of evidence: This study provides Class IV evidence that GCs are effective in delaying LoA in patients with DMD.

Original languageEnglish (US)
Pages (from-to)1048-1055
Number of pages8
Issue number12
StatePublished - Sep 22 2015

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study'. Together they form a unique fingerprint.

Cite this